Products

FLAREX® (fluorometholone acetate ophthalmic suspension) 0.1% is indicated for use in the treatment of steroid-responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the eye.

CONTRAINDICATIONS

FLAREX® suspension is contraindicated in most viral diseases of the cornea and conjunctiva including epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, and varicella, and also in mycobacterial infection of the eye and fungal diseases of ocular structures. FLAREX® suspension is also contraindicated in individuals with known or suspected hypersensitivity to any of the ingredients of this preparation and to other corticosteroids.

WARNINGS AND PRECAUTIONS

Prolonged use of corticosteroids may result in glaucoma with damage to the optic nerve, defects in visual acuity and fields of vision, and in posterior subcapsular cataract formation. Prolonged use may also suppress the host immune response and thus increase the hazard of secondary ocular infections.

ADVERSE REACTIONS

Adverse reactions include, in decreasing order of frequency, elevation of intraocular pressure (IOP) with possible development of glaucoma and infrequent optic nerve damage, posterior subcapsular cataract formation, and delayed wound healing.

DOSAGE AND ADMINISTRATION

Instill one to two drops into the conjunctival sac of the affected eye(s) four times daily. During the initial 24 to 48 hours, the dosage may be safely increased to two drops every two hours.

FRESHKOTE® PF is a preservative-free, polymer-based artificial tear designed to provide long-lasting comfort for dry eye sufferers.

IHEEZO® (chloroprocaine HCl ophthalmic gel) 3% is indicated for ocular surface anesthesia.

CONTRAINDICATIONS

IHEEZO is contraindicated in patients with a known hypersensitivity to chloroprocaine, other ester anesthetics, or any component of the formulation.

WARNINGS AND PRECAUTIONS

Corneal Toxicity: Corneal toxicity may occur with prolonged use. Avoid repeated dosing. Methemoglobinemia: Cases of methemoglobinemia have been reported. Monitor for signs and symptoms.

ADVERSE REACTIONS

The most common adverse reactions (incidence ≥5%) are mydriasis, conjunctival hyperemia, and eye irritation/discomfort.

DOSAGE AND ADMINISTRATION

Apply IHEEZO topically to the ocular surface (cornea and conjunctiva) immediately before the procedure.

ILEVRO® (nepafenac ophthalmic suspension) 0.3% is indicated for the treatment of pain and inflammation associated with cataract surgery.

CONTRAINDICATIONS

ILEVRO is contraindicated in patients with previously demonstrated hypersensitivity to any of the ingredients in the formula or to other NSAIDs.

WARNINGS AND PRECAUTIONS

Increased Bleeding Time: Topical NSAIDs may increase bleeding time due to interference with thrombocyte aggregation. Delayed Healing: Topical NSAIDs may slow or delay healing. Corneal Effects: Use of topical NSAIDs may result in keratitis.

ADVERSE REACTIONS

The most frequently reported ocular adverse reactions following cataract surgery occurring in 5-10% of patients were capsular opacity, decreased visual acuity, foreign body sensation, increased IOP, and sticky sensation.

DOSAGE AND ADMINISTRATION

One drop of ILEVRO should be applied to the affected eye once daily beginning 1 day prior to cataract surgery, continued on the day of surgery and through the first 2 weeks of the postoperative period.

IOPIDINE® (apraclonidine ophthalmic solution) 0.5% is indicated for short-term adjunctive therapy in patients on maximally tolerated medical therapy who require additional IOP reduction.

CONTRAINDICATIONS

IOPIDINE is contraindicated in patients receiving monoamine oxidase (MAO) inhibitors. IOPIDINE is also contraindicated in patients with hypersensitivity to apraclonidine or clonidine.

WARNINGS AND PRECAUTIONS

Cardiovascular Effects: Although the topical use of IOPIDINE has not been studied in patients with cardiovascular disease, caution should be exercised in treating such patients.

ADVERSE REACTIONS

The following adverse reactions were reported in clinical studies: ocular hyperemia, pruritus, discomfort, tearing, dry mouth, and foreign body sensation.

DOSAGE AND ADMINISTRATION

One to two drops in the affected eye(s) three times daily.

MAXIDEX® (dexamethasone ophthalmic suspension) 0.1% is indicated for the treatment of steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe.

CONTRAINDICATIONS

Contraindicated in epithelial herpes simplex keratitis, vaccinia, varicella, and most other viral diseases of the cornea and conjunctiva. Also contraindicated in mycobacterial infection of the eye and fungal diseases of ocular structures.

WARNINGS AND PRECAUTIONS

Prolonged use of corticosteroids may result in elevated IOP and/or glaucoma, with damage to the optic nerve, defects in visual acuity and fields of vision, and posterior subcapsular cataract formation.

ADVERSE REACTIONS

Glaucoma with optic nerve damage, visual acuity and field defects, cataract formation, secondary ocular infection, and perforation of the globe.

DOSAGE AND ADMINISTRATION

Instill one or two drops into the conjunctival sac every hour during the day and every two hours during the night as initial therapy.

MAXITROL® is indicated for steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where superficial bacterial ocular infection or a risk of bacterial ocular infection exists.

CONTRAINDICATIONS

Contraindicated in most viral diseases of the cornea and conjunctiva, mycobacterial infection of the eye, and fungal diseases of ocular structures. Also contraindicated in individuals who have shown hypersensitivity to any of its components.

WARNINGS AND PRECAUTIONS

Prolonged use of corticosteroids may result in glaucoma with damage to the optic nerve, defects in visual acuity and fields of vision, and in posterior subcapsular cataract formation.

ADVERSE REACTIONS

Adverse reactions have occurred with steroid/anti-infective combination drugs which can be attributed to the steroid component, the anti-infective component, or the combination.

DOSAGE AND ADMINISTRATION

One or two drops instilled into the conjunctival sac(s). In severe disease, drops may be used hourly, being tapered to discontinuation as the inflammation subsides.

NATACYN® (natamycin ophthalmic suspension) 5% is indicated for the treatment of fungal blepharitis, conjunctivitis, and keratitis caused by susceptible organisms.

CONTRAINDICATIONS

Contraindicated in individuals with known hypersensitivity to any of its components.

WARNINGS AND PRECAUTIONS

Failure of improvement in keratitis after 7-10 days of administration suggests that the infection may be caused by a microorganism not susceptible to natamycin.

ADVERSE REACTIONS

One case of conjunctival chemosis and hyperemia, thought to be allergic in nature, was reported.

DOSAGE AND ADMINISTRATION

The recommended initial dosage in fungal keratitis is one drop of NATACYN instilled in the conjunctival sac at 1- or 2-hour intervals.

NEVANAC® (nepafenac ophthalmic suspension) 0.1% is indicated for the treatment of pain and inflammation associated with cataract surgery.

CONTRAINDICATIONS

Contraindicated in patients with previously demonstrated hypersensitivity to any of the ingredients in the formula or to other NSAIDs.

WARNINGS AND PRECAUTIONS

Increased Bleeding Time: Topical NSAIDs may increase bleeding time. Delayed Healing: Topical NSAIDs may slow or delay healing. Corneal Effects: Use of topical NSAIDs may result in keratitis. Contact Lens Wear: Should not be administered while wearing contact lenses.

ADVERSE REACTIONS

The most frequently reported ocular adverse reactions following cataract surgery were capsular opacity, decreased visual acuity, foreign body sensation, increased IOP, and sticky sensation.

DOSAGE AND ADMINISTRATION

One drop of NEVANAC should be applied to the affected eye three times daily beginning 1 day prior to cataract surgery, continued on the day of surgery and through the first 2 weeks of the postoperative period.

TOBRADEX® ST is indicated for steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where superficial bacterial ocular infection or a risk of bacterial ocular infection exists.

CONTRAINDICATIONS

Contraindicated in most viral diseases of the cornea and conjunctiva including epithelial herpes simplex keratitis, vaccinia, and varicella. Also contraindicated in mycobacterial infection of the eye and fungal diseases of ocular structures.

WARNINGS AND PRECAUTIONS

IOP increase, cataracts, delayed healing, bacterial infections, viral infections, fungal infections, aminoglycoside sensitivity, and corneal and scleral thinning have been reported.

ADVERSE REACTIONS

The most frequent adverse reactions to topical ocular tobramycin include hypersensitivity and localized ocular toxicity. The reactions due to the steroid component include elevation of IOP, posterior subcapsular cataract formation, and delayed wound healing.

DOSAGE AND ADMINISTRATION

One drop into the conjunctival sac(s) of the affected eye(s) every 4 to 6 hours.

TRIESENCE® (triamcinolone acetonide injectable suspension) 40 mg/mL is indicated for sympathetic ophthalmia, temporal arteritis, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids, and visualization during vitrectomy.

CONTRAINDICATIONS

Contraindicated in patients with systemic fungal infections and in patients who are hypersensitive to any components of this product.

WARNINGS AND PRECAUTIONS

Elevated IOP, cataracts, infections, hypothalamic-pituitary-adrenal axis suppression, Cushing's syndrome, hyperglycemia, immunosuppression, cardio-renal effects, GI effects, musculoskeletal effects, and endocrine effects may occur.

ADVERSE REACTIONS

The following adverse reactions have been associated with corticosteroid therapy: elevated IOP (20-60%), posterior subcapsular cataracts, and secondary ocular infections.

DOSAGE AND ADMINISTRATION

The initial dose of TRIESENCE will vary depending on the specific disease entity being treated.

VERKAZIA® (cyclosporine ophthalmic emulsion) 0.1% is indicated for the treatment of vernal keratoconjunctivitis (VKC) in children and adults.

WARNINGS AND PRECAUTIONS

Potential for Eye Injury and Contamination: To avoid the potential for eye injury and contamination, advise patients not to touch the vial tip to the eye or other surfaces.

ADVERSE REACTIONS

The most common adverse reactions reported in ≥1% of patients were eye pain (12%), ocular pruritus (8%), eye irritation, lacrimation increased, and erythema of eyelid.

DOSAGE AND ADMINISTRATION

Instill one drop of VERKAZIA four times daily (morning, noon, afternoon, and evening) in each affected eye.

VEVYE® (cyclosporine ophthalmic solution) 0.1% is indicated for the treatment of the signs and symptoms of dry eye disease.

WARNINGS AND PRECAUTIONS

Potential for Eye Injury and Contamination: Advise patients not to touch the dropper tip to the eye or any surface to avoid contamination. Contact Lens Wear: Remove contact lenses prior to instillation.

ADVERSE REACTIONS

The most common adverse reactions (incidence ≥1%) reported were instillation site reactions (8%) and visual acuity reduced (3%).

DOSAGE AND ADMINISTRATION

Instill one drop of VEVYE twice daily (approximately 12 hours apart) into each eye.

VIGAMOX® (moxifloxacin HCl ophthalmic solution) 0.5% is indicated for the treatment of bacterial conjunctivitis caused by susceptible strains of organisms.

WARNINGS AND PRECAUTIONS

Topical Ophthalmic Use Only: NOT for injection. Growth of Resistant Organisms: Prolonged use may result in overgrowth of non-susceptible organisms, including fungi. Corneal Endothelium: Not recommended for use in patients who have undergone corneal transplantation.

ADVERSE REACTIONS

The most frequently reported ocular adverse events were conjunctivitis, decreased visual acuity, dry eye, keratitis, ocular discomfort, ocular hyperemia, ocular pain, ocular pruritus, subconjunctival hemorrhage, and tearing.

DOSAGE AND ADMINISTRATION

Instill one drop in the affected eye 3 times a day for 7 days.

ZERVIATE® (cetirizine ophthalmic solution) 0.24% is indicated for the treatment of ocular itching associated with allergic conjunctivitis.

WARNINGS AND PRECAUTIONS

Contamination of Tip and Solution: Advise patients not to touch dropper tip to eyelids or surrounding areas. Contact Lens Wear: Should not be instilled while wearing contact lenses. Topical Ophthalmic Use Only: For topical ophthalmic administration only.

ADVERSE REACTIONS

The most commonly reported adverse reactions occurred in approximately 1-7% of patients. These reactions were ocular hyperemia, instillation site pain, and visual acuity reduced.

DOSAGE AND ADMINISTRATION

Instill one drop in each affected eye twice daily (approximately 8 hours apart).